| 0.2728 -0.003 (-0.98%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.38 | 1-year : | 0.44 |
| Resists | First : | 0.33 | Second : | 0.38 |
| Pivot price | 0.3 |
|||
| Supports | First : | 0.25 | Second : | 0.2 |
| MAs | MA(5) : | 0.27 |
MA(20) : | 0.3 |
| MA(100) : | 0.39 |
MA(250) : | 0.88 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16.4  |
D(3) : | 12.2 |
| RSI | RSI(14): 39.9 |
|||
| 52-week | High : | 2.41 | Low : | 0.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALBT ] has closed above bottom band by 20.1%. Bollinger Bands are 9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.29 - 0.29 | 0.29 - 0.29 |
| Low: | 0.26 - 0.26 | 0.26 - 0.26 |
| Close: | 0.27 - 0.27 | 0.27 - 0.28 |
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
Mon, 22 Apr 2024
Avalon GloboCare launches KetoAir breathalyzer in the U.S. - Investing.com India
Mon, 22 Apr 2024
Avalon GloboCare launches KetoAir breathalyzer in the US - Proactive Investors USA
Mon, 22 Apr 2024
Avalon GloboCare Announces Launch of U.S. Sales of KetoAir - GlobeNewswire
Thu, 28 Mar 2024
Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software ... - GlobeNewswire
Thu, 28 Mar 2024
Avalon GloboCare extends exclusive distribution agreement for KetoAir breathalyzer - Proactive Investors USA
Wed, 06 Mar 2024
ALBT Stock Quote Price and Forecast - CNN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Real Estate
|
|
|
Industry:
Real Estate - Services
|
|
| Shares Out | 11 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 56.5 (%) |
| Held by Institutions | 1.4 (%) |
| Shares Short | 83 (K) |
| Shares Short P.Month | 329 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.29 |
| Profit Margin | 0 % |
| Operating Margin | -166.4 % |
| Return on Assets (ttm) | -25.4 % |
| Return on Equity (ttm) | -89.5 % |
| Qtrly Rev. Growth | 122.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.1 |
| EBITDA (p.s.) | -0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.3 |
| PEG Ratio | 0 |
| Price to Book value | -0.95 |
| Price to Sales | 2.72 |
| Price to Cash Flow | -0.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|